pay for delay

Pay-for-delay pharmaceutical agreements have attracted scrutiny from regulators in the US and EU. With last year's repeal of the intellectual property exemption in the CCA, these agreements are at greater risk of Australian regulatory attention...

Read More →

No more delay on reverse payments

January 11, 2013 | 1 Comments

Louise Beange has written an interesting post on our sister blog, IP Whiteboard, about the decision by the US Supreme Court to hear a dispute over the legality of ‘pay-for-delay’ or reverse-payment agreements between patent...

Read More →